Medicare launched a temporary 18-month pilot program to cover GLP-1 weight-loss drugs for the first time.
The initiative provides millions of seniors and younger individuals with disabilities access to Novo Nordisk’s Wegovy.
Eligible patients will pay a $50 monthly co-payment.
This expanded access is expected to trigger a surge in Wegovy prescriptions.
The program addresses previous barriers including high retail costs and inconsistent private insurance coverage.
Increased availability is expected to significantly impact Novo Nordisk’s total sales in the U.S. market.